Advanced searches left 3/3

Mucous Membrane Pemphigoid - DOAJ

Summarized by Plex Scholar
Last Updated: 16 January 2022

* If you want to update the article please login/register

The Second Study of Clinical and Immunological Findings in Anti-laminin 332-Type Mucous Membrane Pemphigoid Examined at Kurume University—Diagnosis Criteria Suggested by Summary of 133 Cases

A first analysis of LM332-type MMPs identified by our separate inclusion criteria: immunoglobulin G deposition to the basement membrane zone by direct immunofluorescence or IgG reactivity with the dermal side of split skin by ssIIF, with a positive result for at least one of the three subunits of LM332 by immunoblotting of purified human LM332-type MMPs, as well as the presence of mucosal lesion of s The sensitivities of ssIIF and direct immunofluorescence are similar, but indirect immunofluorescence using non-split human skin is significantly higher than indirect immunofluorescence. paraphrasedoutput:Conclusions This retrospective review revealed that autoantibodies against non-LM332 autoantigens may increase the production of anti-LM2 antibodies in 133 cases of anti-LM332-type MMP, in which the new diagnostic criteria without positive direct immunofluorescence reactivity were helpful in diagnosis.

Source link: https://doi.org/10.3389/fimmu.2021.771766


Comparison of Two Diagnostic Assays for Anti-Laminin 332 Mucous Membrane Pemphigoid

Against laminin 332 autoimmune blistering disease is characterized by the presence of predominant mucosal lesions and autoantibodies. This research compared two independently developed diagnostic indirect immunofluorescence tests based on recombinant laminin 332 expression in HEK239 cells and the migration trails of cultured keratinocytes rich in laminin 332 symophils. The sera of 54 anti-laminin 332 MMP, 35 non-anti-laminin 332 MMP, 35 non-anti-laminin 332 MMP, and 30 pemphi vulgaris patients, as well as 20 healthy blood donors, were analyzed blindly and independently. According to say, 54 and 54 percent anti-laminin 332 MMP sera were positive in the biochip mosaic and the footprint.

Source link: https://doi.org/10.3389/fimmu.2021.773720


Mucous Membrane Pemphigoid-Associated Malignancies. Case Series and a Brief Overview of the Literature

Mission: Objective: To present our personal case series of patients with MMP-associated malignancy from a dermatology university hospital. Methods: Twenty-two patients affected by MMP were seen in the period from 2001 to 2016; in four patients, an associated cancer was detected. MMP patients have a relatively high risk of developing a solid cancer, according to our findings, but autoantibody testing is not mandatory and is likely to determine the severity of the disease.

Source link: https://doi.org/10.5826/dpc.0902a07


Treatment strategies in mucous membrane pemphigoid

MutasimDepartment of Dermatology, University of Cincinnati, Ohio, USAAbstract: Mucous membrane pemphigoid is an autoimmune blistering disorder characterized by subequent blistering. Several basement membrane zone components have been identified as autoantibodies in MMP, according to autoantibodies. MMP's clinical presentation is also highly varied. MMP treatment is based on the areas of involvement, medical sensitivity, and disease progression. Because of the rarity of this disease, large controlled studies comparing various agents' effectiveness are lacking.

Source link: https://doaj.org/article/0f72f3213b184feb81299a848c6db53b


A Case of Severe and Refractory Membranous Nephropathy Associated to Mucous Membrane Pemphigoid

Primary membranous nephropathy and mucous membrane pemphigoid are two autoimmune diseases with well-defined diagnostic and treatment guidelines. In certain case reports, MN has been attributed to bullying pemphigoid, but no information is known about the connection between MN and other dangerous diseases. We report a case of severe refractory membranous nephropathy secondary to mucous membrane pemphigoid that has successfully treated with rituximab. Our clinic was referred to a 35-year-old woman with known MMP for new-onset generalized edema and proteinuria. MN can be secondary to MMP, according to this report, and rituximab can be a good source of remission in cases that are resistant to standard therapy.

Source link: https://doi.org/10.1155/2021/9940293

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions